TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and sanofi-aventis are collaborating on the development of Regeneron’s Vascular Endothelial Growth Factor (VEGF) Trap in oncology. On February 13, 2007, sanofi-aventis will report its 2006 annual results and review its development pipeline. As part of this review, sanofi-aventis will provide an update of the VEGF Trap clinical program. The presentation is scheduled to be webcast live beginning at 8:30 a.m. Paris Time (2:30 a.m. Eastern Time) and can be accessed through the sanofi-aventis website (www.sanofi-aventis.com) at the time of the presentation. An archived version of the presentation will be available after the live webcast on the sanofi-aventis website.
